JNJ-70218902 

JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC₅₀: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003)^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

JNJ-70218902 binds to TMEFF2-positive LNCaP-AR cells (EC₅₀: 9.6 nM) but not to TMEFF2-negative DU145 prostate cancer cells^[1].
JNJ-70218902 has a high binding affinity for CD3 on primary human T cells (K_D: 151 nM)^[1].
JNJ-70218902 induces T cell-mediated killing (EC₅₀: 1.4 nM) when incubates with healthy human donor T cells and LNCaP-AR cells at an effector-target ratio of 3:1, and T cell activation is demonstrated by increased cell surface CD8+CD25+ expression and pro-inflammatory cytokines^[1].
JNJ-70218902 shows low cytotoxicity in DU145 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

JNJ-70218902 has antitumor activity at increasing concentrations up to 5 mg/kg in T cell humanized NSG mice bearing LNCaP xenografts (tumor growth inhibition rates of 75-122%) and LuCaP 86.2 patient-derived xenografts (tumor growth inhibition rates of 72-88%)^[1].
JNJ-70218902 (0.075 mg/kg or 0.075 mg/kg, then 0.3 mg/kg after one week) in a cynomolgus monkey model of prostate cancer can induce the infiltration of activated and proliferating T cells and inflammatory cells into the prostate, mediating an effective immune response^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[JNJ-70218902]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Basu S et al. Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models Cancer Research 82.12_Supplement (2022): LB087-LB087.

  [2]. Lowenstein C, et al. 1360 Pharmacodynamics of JNJ-70218902, a TMEFF2× CD3 bispecific antibody, in cynomolgus monkey. (2022).